Literature DB >> 27308249

What's New in Critical Illness and Injury Science? Estrogen: Is it a new therapeutic paradigm for trauma-hemorrhagic shock?

Sanjeev Bhoi1, Shreshtha Tiwari1, Manoj Kumar1.   

Abstract

Entities:  

Year:  2016        PMID: 27308249      PMCID: PMC4901825          DOI: 10.4103/2229-5151.183021

Source DB:  PubMed          Journal:  Int J Crit Illn Inj Sci        ISSN: 2229-5151


× No keyword cloud information.
Hemorrhagic shock (HS) is the most common cause of death after trauma. Mortality due to HS is about 50%.[1] Therapeutic uses of drugs as adjuncts are limited. Fluid, blood component, and control of hemorrhage have been the cornerstone of management. Resuscitation with fluids and blood products induces reperfusion ischemia due to the production of reactive oxygen species and activation of immune cells.[2] Cytokine storm dysregulates balance of pro- and anti-inflammatory cytokines, which leads to suppression of immune system.[3] Raju et al. reported suppression of immune system is characterized by decreased T- and B-cell function. The function of splenic dendritic cells and macrophage antigen presenting function were depressed following trauma-hemorrhage (TH).[3] Immunological alteration or its complication following T/HS may be reversed by estrogen administration.[3] In addition, suppressed cardiac, hepatocellular, and immune functions were maintained with estrogen treatment in male mice, rats, and proestrus females following TH.[34] Raju et al. reported that female tolerate trauma and sepsis stimuli than male and that estrogen has a protective effect.[3] Li et al. showed treatment with estrogen increased vascular reactivity and responsiveness in both male and female rats of 8–24 week. Protective effects of estrogen were associated with G protein-coupled receptor 30, estrogen receptor-mediated Rho kinase, and protein kinase C pathway activation.[1] Sex dichotomies were observed in 7560 males and 2774 females from a large trauma registry. It showed that female sex protects from organ failure and sepsis after major TH.[5] Conjugated intravenous estrogen is used as a therapeutic option for massive dysfunctional uterine bleeding but its role in T/HS has not been defined. Future studies on humans may explore the therapeutic role of estrogen as an adjunct in patients presenting with trauma HS.
  5 in total

Review 1.  Estrogen: a novel therapeutic adjunct for the treatment of trauma-hemorrhage-induced immunological alterations.

Authors:  Raghavan Raju; Kirby I Bland; Irshad H Chaudry
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

2.  Female sex protects from organ failure and sepsis after major trauma haemorrhage.

Authors:  H Trentzsch; U Nienaber; M Behnke; R Lefering; S Piltz
Journal:  Injury       Date:  2014-10       Impact factor: 2.586

3.  Age and sex differences in vascular responsiveness in healthy and trauma patients: contribution of estrogen receptor-mediated Rho kinase and PKC pathways.

Authors:  Tao Li; Xudong Xiao; Jie Zhang; Yu Zhu; Yi Hu; Jiatao Zang; Kaizhi Lu; Tiande Yang; Hengjiang Ge; Xiaoyong Peng; Dan Lan; Liangming Liu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-02-14       Impact factor: 4.733

Review 4.  Gender-Specific Effects on Immune Response and Cardiac Function after Trauma Hemorrhage and Sepsis.

Authors:  Markus Albertsmeier; Sebastian Pratschke; Irshad Chaudry; Martin K Angele
Journal:  Viszeralmedizin       Date:  2014-04

5.  Does erythropoietin reactivate bone marrow dysfunction in trauma hemorrhagic shock?

Authors:  Manoj Kumar; Sanjeev Bhoi
Journal:  Int J Crit Illn Inj Sci       Date:  2015 Oct-Dec
  5 in total
  1 in total

Review 1.  Impaired hematopoietic progenitor cells in trauma hemorrhagic shock.

Authors:  Manoj Kumar; Sanjeev Bhoi
Journal:  J Clin Orthop Trauma       Date:  2016-06-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.